ANIMAL IMAGING CORE

成像研究为非侵入性检测前列腺中重要的关键分子提供了可能性 癌症生物学和医学。小动物成像核心的目标是提供成像研究 为参与定义前列腺癌特征的研究人员提供支持，通常是在分子层面 水平。影像研究可以作为分子变化的非侵入性表型关联。这个 小动物成像核心的主要责任将是提供正电子发射断层扫描 (PET)、单光子发射计算机断层扫描(SPECT)、光学和磁共振成像 以及以最高空间分辨率监测分子效应的光谱能力 用于研究动物模型中癌症生物学的变化。可用的仪器包括2个磁力设备 共振成像/光谱分析系统(4.7T/40厘米直径和7.0T/31厘米直径系统)，2个微PET 荧光和光学成像系统、MicroCT、MicroSPECT和光学成像设备(IVIS) 生物发光成像。小动物成像核心在最后一个间隔期间取得的成就包括 14份出版物和2份赠款，直接与基于孢子资助的研究的小动物成像有关。 根据我们以前的经验，进行的成像研究的很大一部分将集中在 获得高分辨率的解剖成像。这些研究的目标将是发现最低限度的肿瘤 负担，表征增长率，并监测对新疗法的反应。其中一些研究(报告4) 可利用新的成像方案，例如将3‘-脱氧-3’-(18)F-氟胸苷(Flt)成像为 增殖标记物，增殖的磁共振波谱测量(并关联PET和MR数据 和Ki67测量)和动态增强MRI评估抗血管生成 探员们。此外，我们将评估不同的PET放射性核素示踪剂作为潜在的成像 药物包括11C-蛋氨酸、18F-脱氧葡萄糖、18F-氟二氢睾酮和1241- 碘脱氧尿嘧啶核苷)，将与病理数据相关联。主要的重点将是确保 成像检查期间适宜的生理环境(温度控制、心脏和呼吸 费率)。用于同时对多只小鼠进行成像的射频谐振器的构建 将进行吸入麻醉、体温监测等。为了提高空间分辨率，更多 敏感的谐振器线圈将被研究。作为核心设施，主要目标将是提供 ART成像能力，图像处理和分析的改进，以提高多通道的准确性 成像(与其他赠款合作支持)和适当的放射性示踪剂 由纪念斯隆·凯特琳癌症中心的回旋加速器和放射化学核心提供

Imaging studies offer the potential for non-invasive detection of key molecules that are important in prostate cancer biology and medicine. The goal of the Small Animal Imaging Core is to provide imaging research support to investigators who are involved in defining a prostate cancer signature, often at the molecular level. Imaging studies may serve as a non-invasive phenotypic correlate of the molecular changes. The primary responsibility of the Small Animal Imaging Core will be to provide positron emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), optical, and magnetic resonance imaging and spectroscopy capability at the highest spatial resolution possible to monitor the effect of molecular changes and for the study of cancer biology in animal models. Available instrumentation include 2 magnetic resonance imaging/spectroscopy systems (4.7T/40 cm bore and 7.0T/31 cm bore systems), 2 MIcroPET systems, MicroCT, MicroSPECT, and optical imaging equipment (IVIS) for fluorescence and bioluminescence imaging. Achievements of the Small Animal Imaging Core during the last interval include 14 publications and 2 grants directly related to small animal imaging based on SPORE funded research. Based on our previous experience, a significant portion of the imaging research performed will focus on obtaining high resolution anatomic imaging. The goals of these studies will be to detect tumor at minimal burden, characterize growth rates, and monitor response to novel therapies. Some of these studies (RP4) may utilize novel imaging schemes such as imaging 3'-deoxy-3'-(18)F-fluorothymidine (FLT) as a proliferation marker, MR spectroscopic measurements of proliferation (and correlate the PET and MR data with each other and Ki67 measurements), and dynamic contrast enhanced MRI to evaluate antiangiogenesis agents. In addition, we will evaluate different PET radionuclide tracers as potential imaging agents including 11C-methionine, 18F-fluorodeoxyglucose, 18F-fluorodihydrotestosterone and 1241- iododeoxyuridine) which will be correlated with pathologic data. A major emphasis will be to assure a physiologically appropriate environment during imaging studies (temperature control, heart and respiratory rate). Construction of a radiofrequency resonator designed to image multiple mice simultaneously with inhalation anesthesia, temperature monitoring etc. will be done. To enhance spatial resolution, more sensitive resonators coils will be investigated. As a core facility, the main goal will be to provide state of the art imaging capability, improvements in image processing and analysis to enhance the accuracy of multimodality imaging (supported in collaboration with other grants), and appropriate radiotracers which will be provided by the Cyclotron and Radiochemistry Core of Memorial Sloan Kettering Cancer Center